Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645027 | 1.00 | IRAK4 (0.53) | IRAK4NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL30645121 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL20743189 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL20743761 | 0.83 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL30645019 | 0.83 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL20743099 | 0.83 | RAB9A (0.48) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL28429125 | 0.82 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2HTTMEN1 | |
| SCHEMBL20743140 | 0.82 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL30645024 | 0.82 | SMN1; SMN2 (0.47) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL20743025 | 0.82 | MTOR (0.49) | NPC1RAB9ASMN1; SMN2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | claimed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | claimed |
| CN-111344281-A | Potassium channel inhibitors of substituted benzimidazoles | 阿塞西翁制药公司 | 2020-06-26 | — | — | CN | claimed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | claimed |
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| CN-111344281-A | Potassium channel inhibitors of substituted benzimidazoles | 阿塞西翁制药公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | IRAK4 2044/4885NPC1 298/4885RAB9A 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.